The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics, announced today the close of a $92 million Series A financing round led by ...

Pinnacle Associates Ltd. cut its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 2.1% during the third ...

Tectonic Advisors LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 6.6% during the 3rd ...

Shares of several bitcoin-related companies, including trading app Robinhood (HOOD), cryptocurrency exchange Coinbase Global (COIN) and Marathon Digital parent company MARA Holdings (MARA ... $6 ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Treace Medical Concepts (TMCI – Research Report), ...

Investors will be looking to the latest report from Warren Buffett's firm Berkshire Hathaway (BRK-B), to garner any insights ...

(Reuters) - Contract drug manufacturer Catalent, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.